Patched Homolog (PTCH1) Gene as a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation With Early Response to First-Line of Treatment Imatinib

被引：0
|
作者：
Rakha, Nahed Moawad [1 ]
Moahmed, Tamer [1 ]
Said, Rasha Magdy M. [1 ]
Ali, Esraa [1 ]
Abdulla, Nour Elhuda [1 ]
机构：
[1] Ain Shams Univ, Internal Med Dept, Clin Hematol Div, Fac Med, Cairo, Egypt
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CML; PTCH1; chronic phase; patched homolog gene; ELISA; imatinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-024
引用
收藏
页码：S331 / S331
页数：1
相关论文
共 50 条
  • [41] Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib
    Ailawadhi, Sikander
    Akard, Luke P.
    Miller, Carole B.
    Jillella, Anand
    DeAngelo, Daniel J.
    Ericson, Solveig G.
    Lin, Felice
    Warsi, Ghulam
    Radich, Jerald
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (01) : 3 - 12
  • [42] Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia
    Ni, Ling-Na
    Li, Jian-Yong
    Miao, Kou-Rong
    Qiao, Chun
    Zhang, Su-Jiang
    Qiu, Hai-Rong
    Qian, Si-Xuan
    MEDICAL ONCOLOGY, 2011, 28 (01) : 265 - 269
  • [43] MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis
    Zu, Bailing
    Li, Yajuan
    Wang, Xin
    He, Dali
    Huang, Zhenglan
    Feng, Wenli
    PHARMACOGENOMICS, 2014, 15 (05) : 667 - 677
  • [44] Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
    Marin, David
    Hedgley, Corinne
    Clark, Richard E.
    Apperley, Jane
    Foroni, Letizia
    Milojkovic, Dragana
    Pocock, Christopher
    Goldman, John M.
    O'Brien, Stephen
    BLOOD, 2012, 120 (02) : 291 - 294
  • [45] Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia
    Ling-Na Ni
    Jian-Yong Li
    Kou-Rong Miao
    Chun Qiao
    Su-Jiang Zhang
    Hai-Rong Qiu
    Si-Xuan Qian
    Medical Oncology, 2011, 28 : 265 - 269
  • [46] Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia
    Nardinelli, Luciana
    Sanabani, Sabri Saeed
    Didone, Alline
    Ferreira, Patricia de Barros
    Serpa, Mariana
    Yoshinaga Novaes, Mafalda Megumi
    Marchiani, Mariana
    Ruiz, Antonio Lancha
    Lima, Ismael Severino
    Fischer Chamone, Dalton de Alencar
    Bendit, Israel
    ACTA HAEMATOLOGICA, 2012, 127 (04) : 228 - 234
  • [47] SHP-1 expression in chronic myeloid leukemia: clinical significance and impact on response to imatinib treatment
    Heiba, Nihal M.
    Elshazly, Shereen A.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2013, 38 (02) : 84 - 89
  • [48] Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis
    Sheng, Guangying
    Chen, Suning
    Dong, Chaohui
    Zhang, Ri
    Miao, Miao
    Wu, Depei
    Tan, Seng Chuen
    Liu, Chao
    Xiong, Tengbin
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 371 - 381
  • [49] Changes in expression of apoptosis-related genes are linked to the molecular response to imatinib treatment in chronic-phase chronic myeloid leukemia patients
    Wei, Yuan
    Stockelberg, Dick
    Hullberg, Sara
    Ricksten, Anne
    Wadenvik, Hans
    ACTA HAEMATOLOGICA, 2007, 117 (02) : 83 - 90
  • [50] Assessment of BCR-ABL1 Fusion Transcripts and Their Association with Response to Imatinib Treatment in Chronic Myeloid Leukemia Patients
    Kagita, Sailaja
    Mamidi, Tulasi Krishna
    Digumarti, Leela
    Gundeti, Sadasivudu
    Digumarti, Raghunadharao
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2018, 39 (02) : 165 - 171
12345